Targeting SPHK‐S1P‐S1PR signaling, including SP1, SPHK1, SPHK2, S1PR1, and S1PR2 by the use of specific inhibitors, represents an innovative strategy for anticancer therapy that has shown efficacy in in vitro studies and in tumor xenograft models.269. This evidence concerns the gene SPHK1 and neoplasm.